Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02448 |
Influenza A H3N2 Neuraminidase/NA Protein
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 Neuraminidase/NA Protein is expressed in HEK293 mammalian cells. The accession number is C0LU95. | |||
TMPY-02336 |
Influenza A H3N2 (A/Babol/36/2005) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Babol/36/2005) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 49.6 kDa and the accession number is C0LU95. | |||
TMPY-00602 |
Influenza A H3N2 (A/Aichi/2/1968) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Aichi/2/1968) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.8 kDa and the accession number is Q75VQ4.1. | |||
TMPY-06066 |
Influenza A H3N2 (A/Kansas/14/2017) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | Baculovirus Insect Cells |
Influenza A H3N2 (A/Kansas/14/2017) Neuraminidase/NA Protein (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 54.6 kDa and the accession number is A0A2L2FIU4. | |||
TMPY-05205 |
Influenza A H3N2 (A/Hong Kong/4801/2014) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Hong Kong/4801/2014) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.5 kDa. | |||
TMPY-02339 |
Influenza A H3N2 Neuraminidase/NA Protein (R292K)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 Neuraminidase/NA Protein (R292K) is expressed in HEK293 mammalian cells. The accession number is C0LU95. | |||
TMPY-02338 |
Influenza A H3N2 Neuraminidase/NA Protein (N294S)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 Neuraminidase/NA Protein (N294S) is expressed in HEK293 mammalian cells. The accession number is C0LU95. | |||
TMPY-04338 |
Influenza A H3N2 Neuraminidase/NA Protein (H274Y)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 Neuraminidase/NA Protein (H274Y) is expressed in HEK293 mammalian cells. The accession number is C0LU95. | |||
TMPY-02337 |
Influenza A H3N2 Neuraminidase/NA Protein (E119V)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 Neuraminidase/NA Protein (E119V) is expressed in HEK293 mammalian cells. The accession number is C0LU95. | |||
TMPY-04849 |
Influenza A H3N2 (A/Aichi/2/1968) Neuraminidase/NA Protein
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Aichi/2/1968) Neuraminidase/NA Protein is expressed in HEK293 mammalian cells. The predicted molecular weight is 52.2 kDa and the accession number is Q75VQ4.1. | |||
TMPY-06163 |
Influenza A H3N2 (A/Cambodia/e0826360/2020) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | Baculovirus Insect Cells |
Influenza A H3N2 (A/Cambodia/e0826360/2020) Neuraminidase/NA Protein (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 54.7 kDa. | |||
TMPY-06489 |
Influenza A H3N2 (A/Darwin/9/2021) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | Baculovirus Insect Cells |
Influenza A H3N2 (A/Darwin/9/2021) Neuraminidase/NA Protein (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 58.88 kDa. | |||
TMPY-05938 |
Influenza A H3N2 (A/Albany/18/1968) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Albany/18/1968) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.8 kDa and the accession number is A4JZ31. | |||
TMPY-05941 |
Influenza A H3N2 (A/Amsterdam/4112/1992) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Amsterdam/4112/1992) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.8 kDa and the accession number is H9XD32. | |||
TMPY-06446 |
Influenza A H3N2 (A/England/42/1972) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | Baculovirus Insect Cells |
Influenza A H3N2 (A/England/42/1972) Neuraminidase/NA Protein (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 54.78 kDa. | |||
TMPY-05944 |
Influenza A H3N2 (A/Australia/NHRC0001/2005) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Australia/NHRC0001/2005) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.6 kDa and the accession number is F6GNP5. | |||
TMPY-05940 |
Influenza A H3N2 (A/swine/Italy/526/1985) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/swine/Italy/526/1985) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.7 kDa and the accession number is E6XUG9. | |||
TMPY-05939 |
Influenza A H3N2 (A/Hong Kong/107/1971) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Hong Kong/107/1971) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.6 kDa and the accession number is H9XCF2. | |||
TMPY-06470 |
Influenza A H3N2 (A/Hong Kong/2671/2019) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Hong Kong/2671/2019) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 51.08 kDa. | |||
TMPY-05942 |
Influenza A H3N2 (A/Hong Kong/CUHK19579/1998) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/Hong Kong/CUHK19579/1998) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.4 kDa and the accession number is B5ALX7. | |||
TMPY-06889 |
Influenza A H3N2 (A/Hong Kong/01/1968) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | Baculovirus Insect Cells |
Influenza A H3N2 (A/Hong Kong/01/1968) Neuraminidase/NA Protein (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 54.82 kDa. | |||
TMPY-05950 |
Influenza A H3N2 (A/swine/China/JG20/2019) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | HEK293 Cells |
Influenza A H3N2 (A/swine/China/JG20/2019) Neuraminidase/NA Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 50.6 kDa and the accession number is A0A6B9KHK7. | |||
TMPY-06182 |
Influenza A H3N2 (A/Singapore/INFIMH-16-0019/2016) Neuraminidase/NA Protein (His)
NA Protein |
H3N2 | Baculovirus Insect Cells |
Influenza A H3N2 (A/Singapore/INFIMH-16-0019/2016) Neuraminidase/NA Protein (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 54.7 kDa. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01449 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CT6.1,CTAG1,LAGE-2,MY-ESO-1,NY-ESO-1,E... |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01445 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.1,MAGE1,MAGE-1,MAGE-A |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-feto<... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01442 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
HLA-A,P53,TP53,LFS1,MHC,BCC7,TRP53,FLJ9294... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPa |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01480 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
IAP4,Survivin,API4,BIRC5,MHC,MHC I,EPR-1,s... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01527 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
NS,RALD,C-K-RAS,RASK2,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01500 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi)
CTAG1,CT6.1,CTAG1B,LAGE2A |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01539 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CTAG1B,CT6.1,MY-ESO-1,LAGE2A,NY-E... |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
------------------------ 更多 ------------------------ |